< >

HyperAcute Immunotherapy

NewLink Genetics has multiple HyperAcute immunotherapies currently under development in a variety of tumors

Phase 3 Trial in Pancreatic Cancer

Now enrolling patients with borderline resectable or locally advanced unresectable pancreatic cancer

Phase 2b/3 Trial in Lung Cancer

Now enrolling patients with progressive or relapsed non-small cell lung cancer (NSCLC)

Investor Relations

Keep up with the latest news and presentations
Merck and NewLink Genetics Enter Into Licensing and Collaboration Agreement for Investigational Ebola Vaccine
November 24, 2014

NewLink Genetics to Participate in the Upcoming Stifel, Jeffries, and Piper Jaffray Healthcare Conferences
November 17, 2014

ANNOUNCEMENTS